Historique
Article de Périodique
An open-label pilot study of risperidone in the treatment of methamphetamine dependence (2007)
(Etude pilote non masquée de Rispéridone dans le traitement de la dépendance à la méthamphétamine)
Auteur(s) :
MEREDITH, C. W. ;
JAFFE C. ;
YANASAK E. ;
CHERRIER M. ;
SAXON, A. J.
Année
2007
Page(s) :
167-172
Langue(s) :
Anglais
Refs biblio. :
46
Domaine :
Drogues illicites / Illicit drugs
Note générale :
Journal of Psychoactive Drugs, 2007, 39, (2), 167-172
Note de contenu :
tabl.
Résumé :
ENGLISH :
Psychopharmacological treatments for methamphetamine (MA) dependence have questionable efficacy. Open-label risperidone was evaluated in veterans seeking MA dependence treatment. Participants (N=11) received four weeks of risperidone. They provided weekly self-reports of substance use, urine drug screens, and adverse effects. Neuropsychological assessments and psychiatric symptomatology (Brief Symptom Inventory; BSI) were measured at baseline and follow-up. The eight completers had an average risperidone dose of 3.6mg/day and decreased days of MA use during the trial from a mean of 13.0 (SD = 6.5) in the 30 days prior to starting risperidone to a mean of 0.125 (SD = 0.4; = 5.7, p = .001). When measured over time, fine motor function (Grooved Peg Board Dominant Hand) was the only neuropsychological domain to improve significantly. No other domain changed significantly from baseline to follow-up among study completers. BSI data were converted to demographically corrected T-scores utilizing appropriate normative data (mean = 50, SD = 10). BSI somatization T-scores declined from a mean of 59.0 (SD = 8.4) to 51.8 (SD = 8.3; t= 2.7, p <.05), and positive symptom distress declined from a mean of 52.8 (SD = 8.0) to 41.7 (SD = 8.6; t = 3.0, p <.05). Risperidone was well tolerated and associated with decreased MA use. (Author' s abstract)
Affiliation :
Etats-Unis. United States.
Cote :
Abonnement